In the closing days of 2023, Cuu Long Pharmaceutical Joint Stock Company (DCL) organized a Supplier Conference attended by 44 strategic partners and suppliers. The conference was a complete success, exceeding expectations.
The conference served as a bridge to create a tight cooperation network between Cuu Long Pharmaceuticals and its partners, aiming towards common goals: connection, sharing, and seizing market opportunities.
The 2023 Supplier Conference opened up long-term cooperation opportunities.
At the conference, the company’s leadership reviewed DCL’s important milestones during its foundation and development. Established in 1976, and with over 47 years of development, DCL is a major pharmaceutical and medical supplies manufacturer and distributor in the Vietnamese market, with a distribution system spanning all 63 provinces and continuing to expand. Especially since becoming a member of F.I.T Group in 2015 and receiving systematic investments in strategy, finance, and personnel from the Group, DCL has made significant leaps, breaking its revenue record by surpassing 1,000 billion VND in 2022. Furthermore, in its 47-year long journey, DCL has received numerous prestigious awards such as: the SECOND CLASS LABOR ORDER awarded by the President of the Socialist Republic of Vietnam; the first edition of the “VIETNAMESE DRUG STAR” award from the Ministry of Health; TOP 10 leading brands in Vietnam in 2022; Top 10 Prestigious Brands in Asia; Top 10 leading brands in Vietnam; and more.
With the mission of “Connecting and improving community life through optimal health solutions,” DCL aims to become the top highly-regarded Vietnamese pharmaceutical company by patients, partners, and employees through the most innovative, accessible, and best-care products and services.
Mr. Luong Trong Hai – CEO of DCL speaking at the event.
Also at the conference, Mr. Luong Trong Hai announced the business strategy and plan for 2024 to partners and suppliers. He introduced the major projects that DCL is implementing in three key areas: Pharmaceuticals – Medical Equipment – Empty Capsules.
In the Pharmaceutical industry, DCL is currently investing in an EU-GMP standard pharmaceutical factory with a total investment of 1.035 trillion VND. The production capacity of medicines and pharmaceuticals at the factory is 1.6 billion products/year.
In the manufacture and supply of empty capsules industry, Cuu Long Pharmaceuticals is expanding its Vicancap factory as scheduled. It is expected that in January 2024, when the capsule line 5 becomes operational, the supply capacity will reach 9.6 billion capsules/year, equivalent to about 800 million capsules/month.
In the medical equipment industry, with the goal of enhancing production capacity and meeting domestic needs while aiming for international markets, DCL continues to ensure the construction progress of the Benovas Medical Equipment Factory. The project covers an area of 11,000m2, with a total investment of 373 billion VND, divided into two phases and is expected to be operational by the second quarter of 2024.
“Despite market challenges, Cuu Long Pharmaceuticals remains steadfast in its goal of sustainable development. We invest in expansion and construction of new factories to meet the increasing market demands. In 2024, Cuu Long Pharmaceuticals is determined to maintain growth, cooperate with partners and suppliers for mutual development and breakthroughs,” shared Mr. Hai.
The 2023 Supplier Conference promised to open up opportunities for long-term cooperation in the future.
The 2023 Supplier Conference concluded in a spirit of unity and determination for cooperation and development among all parties. The event was an opportunity for DCL and its partners and suppliers to strengthen their cooperative relationship, opening a new chapter of groundbreaking business results in the future.
